Unknown OBSERVATIONAL NCT03057457

The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

Sponsor: BioPorto Diagnostics

Interventions NGAL Test

Updated 8 times since 2017 Last updated: Mar 30, 2017 Started: Mar 31, 2017 Primary completion: Dec 31, 2017 Completion: Feb 28, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Kidney Injury, this trial is ongoing. The trial is conducted by BioPorto Diagnostics and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Feb 2020 — Jan 2021 [monthly]

Unknown Status
Apr 2019 — Feb 2020 [monthly]

Unknown Status

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Apr 2019 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Apr 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioPorto Diagnostics

Data source: BioPorto Diagnostics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Denver, United States